A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Carbon dioxide (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Sponsors Soleno Therapeutics
- 07 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
- 06 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.
- 25 Feb 2016 Capnia expects to report top-line data from this trial by the end of 2016, according to a company media release.